Beam Therapeutics Inc. (BEAM): Shareholders' Equity
$1.24B
As of 2025-12-31
$1.07B
As of 2026-06-30
+19.1%
3-year compound annual growth
+38.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.24B | +68.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $733.54M | -25.2% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $981.33M | +33.8% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $733.47M | -11.3% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $826.74M | +236.7% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $245.56M | n/m | 2023-02-28, Balance as of period end |
| 2019-12-31 | -$201.10M | n/a | 2022-02-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $1.24B | +68.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $233.06M | +4.5% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | -$38.50M | n/m |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $508.59M | -29.0% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $102.73M | -60.4% |
| Agenus Inc (AGEN) | 2025-12-31 | -$271.11M | n/m |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | -$500.47M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $11.85M | -70.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $158.94M | -1.5% |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗